Context Therapeutics (CNTX) Q3 2026 earnings summary

Executive summary

• Portfolio focused on CTIM-76 and CT-202 after internal CT-95 development ended; trial wind-down is expected to finish promptly, with no future material program costs expected.

• CTIM-76 weekly dosing showed a 22% confirmed ORR, 56% DCR and 5.6-month median PFS in heavily pretreated PROC patients; Q3W escalation advanced to 420 µg.

• Q3 2026 net loss was $7.6M; cash of $34.4M is expected to fund operations to early Q4 2027, but substantial doubt about going concern remains.

Financial highlights

• Q3 R&D expense was $5.7M vs. $8.7M in Q3 2025, down 34%; lower CT-202 costs drove the decrease, partly offset by higher CTIM-76, CT-95 and personnel costs.

• Q3 G&A was $2.2M vs. $1.9M; net loss was $7.6M vs. $9.7M, and interest income fell 60% YoY to $0.3M.

• 9M R&D rose 26% YoY to $25.3M, G&A rose 19% to $7.0M, and net loss increased 34% to $30.9M; interest income fell 53% to $1.3M.

• Operating cash use was $25.0M in 9M 2026 vs. $17.4M in 9M 2025; cash and equivalents declined to $34.4M from $66.0M at Dec. 31, 2025.

Outlook and guidance

• Cash at Sept. 30, 2026 is expected to fund operations to early Q4 2027, but estimates depend on assumptions and cash could be used sooner than expected.

• CTIM-76 Phase 1b dose expansion is expected to start in Q1 2027; initial Q3W Phase 1a efficacy data are expected in Q2 2027.

• Initial CT-202 Phase 1a data are expected in 2H 2027; a U.S. IND filing is on track by year-end 2026.

• Additional capital is required; potential sources include equity or debt offerings, collaborations, strategic transactions, and licensing or marketing arrangements.